KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

Xichun Hu, Qingyuan Zhang, Tao Sun, Huihua Xiong, Wei Li, Yuee Teng, Yen-Shen Lu, Ling-Ming Tseng, Min Yan, Hongsheng Li, Danmei Pang, Shin-Cheh -Chen, Wenyan Chen, Ou Jiang, Jingfen Wang, Xinhong Wu, Xian Wang, Aimin Zang, Xiaojia Wang, Julie M Collins, Ethan Fan, Lin Jiang, Xiaoling Zeng, Nicholas C Turner

Nat Commun 16(1) 4324

PMID40346047
PMCIDPMC12064754
DOI10.1038/s41467-025-59210-6
发表日期2025-05-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

In the global CAPItello-291 randomized phase 3 study (NCT04305496) in patients with hormone receptor-positive/HER2-negative advanced breast cancer and progression during/after aromatase inhibitor treatment, capivasertib-fulvestrant significantly improved progression-free survival (PFS) in the overall population and patients with PIK3CA/AKT1/PTEN-altered tumors versus placebo-fulvestrant. We assessed efficacy and safety of capivasertib-fulvestrant in a prespecified exploratory analysis of a Chinese cohort (n = 24) and extended study with the same protocol (n = 110). Clinically meaningful PFS benefit for capivasertib-fulvestrant was observed in the overall population (median PFS: 6.9 [capivasertib-fulvestrant] versus 2.8 [placebo-fulvestrant] months; hazard ratio 0.51, 95% CI 0.34-0.76), patients with PIK3CA/AKT1/PTEN-altered tumors (n = 46; 5.7 versus 1.9 months; hazard ratio 0.41, 95% CI 0.19-0.85) and PIK3CA/AKT1/PTEN-non-altered tumors (patients with confirmed next-generation sequencing results [n = 68]; 9.2 versus 2.7 months; hazard ratio 0.38; 95% CI 0.21-0.68). The most frequent adverse events (AEs) with capivasertib-fulvestrant were diarrhea (60.6% versus 11.3% with placebo-fulvestrant) and hyperglycemia (57.7% versus 17.7%). AEs leading to capivasertib-fulvestrant discontinuation were reported in 11.3% of patients versus 3.2% for placebo-fulvestrant. The benefit-risk profile of capivasertib-fulvestrant in the Chinese cohort was favorable; further exploration in patients with PIK3CA/AKT1/PTEN-non-altered tumors is warranted.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 1

Fig. 1. Investigator-assessed PFS. Reported for A , the Chinese cohort overall population and B , patients with PIK3CA/AKT1/PTEN -altered tumors. The hazard ratio of the capivasertib–fulvestrant (purple) and placebo–fulvestrant (blue) curves was estimated with the use of the Cox proportional hazards model, with stratification according to the presence or absence of liver metastases and previous use of a CDK4/6 inhibitor (yes or no) in the overall population, and according to previous CDK4/6 inhibitor use in the population of patients with PIK3CA/AKT1/PTEN -altered tumors. Tick marks indicate censored data. AKT1 Akt serine/threonine kinase 1, CDK4/6 cyclin-dependent kinase 4/6, CI confidence interval, PIK3CA catalytic subunit alpha of phosphatidylinositol-3-kinase, PFS progression-free survival, PTEN phosphatase and tensin homolog.

A

PFS

Fig. 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

Fig. 1 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Fig. 3

Fig. 3. Overall survival. Reported for A , the Chinese cohort overall population and B , patients with PIK3CA/AKT1/PTEN -altered tumors. The hazard ratio of the capivasertib–fulvestrant (purple) and placebo–fulvestrant (blue) curves was estimated with the use of the Cox proportional hazards model, with stratification according to the previous use of a CDK4/6 inhibitor (yes or no) in the overall population. Results for the population of patients with PIK3CA/AKT1/PTEN -altered tumors are not presented due to an insufficient number of events (<20 across treatment groups). A sufficient number of deaths for a formal analysis of overall survival had not occurred by the data cutoff date (8 May 2023). Tick marks indicate censored data. A 0.01% alpha penalty was assigned to the overall survival analyses of no detriment (i.e. with the hazard ratio not favoring the placebo–fulvestrant group). AKT1 Akt serine/threonine kinase 1, CDK4/6 cyclin-dependent kinase 4/6, CI confidence interval, NA non-applicable, NC not calculated, OS overall survival, PIK3CA catalytic subunit alpha of phosphatidylinositol-3-kinase, PFS progression-free survival, PTEN phosphatase and tensin homolog.

A

Overall survival

Fig. 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Overall survival

Fig. 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 2Fig. 2. Subgroup analysis of investigator-assessed PFS in the Chinese cohort overall population. Subgroup analysis within the overall population was performed at each subgroup level with the use of a Cox proportional hazards model, including the trial-group term only. Data are presented as unstratified HRs and 95% CI. Selected subgroups of interest are shown. Menopausal status was assessed in women only. a Hazard ratio and 95% CI were not calculated due to an insufficient number of events (<20 across treatment groups). CDK4/6 cyclin-dependent kinase 4/6, CI confidence interval, NC not calculated, PFS progression-free survival.
非 KM Figure